Economic Evaluation of SQ-standardized Grass Allergy Immunotherapy Tablet (Grazax®) in Children

ClinicoEconomics and Outcomes Research - New Zealand
doi 10.2147/ceor.s44079
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Prs40 - Cost-Effectiveness of the Sq® Grass Sublingual Immunotherapy (Slit) Tablet in a Paediatric Population

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy and Safety of Timothy Grass Allergy Immunotherapy Tablets in North American Children and Adolescents

Pediatrics
Child HealthPediatricsPerinatology
2011English

Biomarkers of 12 SQ House Dust Mite Sublingual Immunotherapy (SLIT)-Tablet Treatment After Nasal Allergen Challenge

Journal of Allergy and Clinical Immunology
AllergyImmunology
2017English

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Young Children

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy of House Dust Mite Sublingual Immunotherapy-Tablet in Tree and/or Grass Poly-Sensitized Subjects

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy and Safety of the SQ-House Dust Mite Sublingual Immunotherapy Tablet in North American Children and Adults: Findings From a Large Randomized, Placebo-Controlled Clinical Trial

Journal of Allergy and Clinical Immunology
AllergyImmunology
2016English

Implementation of Pre-Seasonal Sublingual Immunotherapy With a Five-Grass Pollen Tablet During Optimal Dosage Assessment

Clinical and Experimental Allergy
AllergyImmunology
2009English

Evaluation of Peanut Sublingual Immunotherapy for Peanut Allergy: A Pilot Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

International Consensus on Allergy Immunotherapy

Journal of Allergy and Clinical Immunology
AllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy